125I粒子植入放疗在儿童眼眶横纹肌肉瘤综合治疗中的应用

doi:10.3760/cma.j.cn115909-20191205-00324

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF 739KB HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：观察125I粒子植入放疗在儿童眼眶横纹肌肉瘤综合治疗中的效果与并发症。方法：回顾性系列病例研究。收集2013年1月至2017年1月在郑州大学第一附属医院收治的8例儿童眼眶横纹肌肉瘤患儿的临床资料。所有患儿均经手术切除和病理检查确诊，根据WHO制定的病理组织学分型标准分为胚胎型6例，腺泡型2例。根据美国横纹肌肉瘤研究协作组（IRSG）分期标准分为Ⅰ期1例，Ⅱ期3例，Ⅲ期4例。所有患儿均在儿科规范化疗，计划在肿瘤切除术后1个月行125I粒子植入放疗。随访项目包括肿瘤控制情况和放疗并发症情况。结果：4例手术中肉眼切除干净，另4例因边界欠清晰未切除干净。7例患者按照各自预定方案完成了化疗，1例未完成化疗并放弃后续治疗。完成综合性治疗的7例患儿4年无瘤生存率为100%，中位随访时间48（37～66）个月。未完成综合治疗方案者1例，因脑转移死亡（眼眶部位稳定控制）。穿刺并发症：1例穿刺道出血。放疗并发症：早期（≤6个月）有角膜刺激征5例，睫毛眉毛脱失5例，局部皮肤色素沉着2例；晚期（>6个月）有视力下降5例，眼表新生血管性病变5例，局部皮肤色素沉着5例，皮下组织萎缩、硬化4例，角膜刺激征3例，睫毛眉毛脱失2例，新生血管性青光眼2例（其中角膜溃疡、穿孔并摘除眼球1例）。所有患儿均无眼眶及面骨发育异常，存活的7例患儿中有6例完整保留眼球，3例视力无影响。结论：包含125I粒子植入内照射的综合治疗可较好地治疗儿童局限于眼眶内的横纹肌肉瘤，但粒子特有的并发症需要进一步观察。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：眼眶横纹肌肉瘤, 粒子植入, 治疗效果, 并发症

Abstract：Objective: To observe the effects and complications of radioactive 125I seeds implantation brachytherapy in the comprehensive treatment of pediatric orbital rhabdomyosarcoma. Methods: This was a retrospective case series study. Eight pediatric cases with orbital rhabdomyosarcoma were treated and followed up from January 2013 to January 2017 in the First Affiliated Hospital of Zhengzhou University. All pediatric patients were treated by surgery, and were diagnosed by pathological examination. There were 6 cases with the embryonal type and 2 cases with the acinar type according to the histopathological classification standard developed by WHO. Based on the Intergroup Rhabdomyosarcoma Study Group (IRSG) stages: 1 case was in stage Ⅰ, 3 cases were in stage Ⅱ, and 4 cases were in stage Ⅲ. All children received standard chemotherapy in pediatrics, and radioactive 125I seeds implantation brachytherapy was planned 1 month after resection. The curative effects and radiation complications were observed. Results: The tumors of 4 patients were completely and cleanly removed in the surgeries, and the others were not. Seven cases completed the comprehensive treatments. The 4-year tumor-free survival rate was 100%, except for 1 patient who did not complete the original chemotherapy plan. This patient eventually died due to brain metastases even though the orbital area was controlled. Follow-up was conducted with a median follow-up time of 48 months (37 to 66 months). Puncture complication: There was 1 case with a puncture hemorrhage. The short-term complications of radiotherapy (less than 6 months): There were 5 cases with irritating corneal symptoms and eyelashes and eyebrows missing, and 2 cases with local skin pigmentation. The long-term complications of radiotherapy (after 6 months): There were 5 cases with local skin pigmentation, 5 cases with ocular surface neovascularization and visual loss, 4 cases with subcutaneous atrophy and sclerosis, 3 cases with corneal irritating symptoms, 2 cases with eyelashes and eyebrows missing, and 2 cases with neovascular glaucoma. The eyeball of 1 patient was removed because of corneal ulcer and perforation. All of the pediatric patients had no abnormalities in the orbital or facial bones. The eyeballs remained intact in 6 cases among the 7 surviving children, and visual acuity was not affected in 3 cases. Conclusions: Pediatric orbital rhabdomyosarcoma that is limited can be treated better by surgery, chemotherapy and radioactive 125I seeds implantation brachytherapy, but the unique complications of radioactive 125I seeds need further study.

Key words： orbital rhabdomyosarcoma seeds implantation curative effects complications

收稿日期: 2019-12-05

通讯作者: 朱豫（ORCID：0000-0001-5137-334X），Email：13673666718@163.com

引用本文:

庞旭杨锦鹏张珂王丽丽朱豫. 125I粒子植入放疗在儿童眼眶横纹肌肉瘤综合治疗中的应用[J]. 中华眼视光学与视觉科学杂志, 2020, 22(4): 293-298. Xu Pang, Jinpeng Yang, Ke Zhang, Lili Wang, Yu Zhu. Application of Radioactive 125I Seeds Implantation Brachytherapy in the Comprehensive Treatment of Pediatric Orbital Rhabdomyosarcoma. Chinese Journal of Optometry Ophthalmology and Visual science, 2020, 22(4): 293-298. DOI: 10.3760/cma.j.cn115909-20191205-00324

链接本文:

https://www.cjoovs.com/CN/10.3760/cma.j.cn115909-20191205-00324 或 https://www.cjoovs.com/CN/Y2020/V22/I4/293

[1]	黄东生, 张谊. 125I-放射性粒子植入术治疗儿童头颈部横纹肌肉瘤研究进展. 中国小儿血液与肿瘤杂志, 2016, 21(2): 57- 59. DOI: 10.3969/j.issn.1673-5323.2016.02.001.
[2]	Ge X, Ma J, Dai H, et al. Clinical research on the treatment effects of radioactive125I seeds interstitial brachytherapy on children with primary orbital rhabdomyosarcoma. Medical Oncology, 2014, 31(9): 27. DOI: 10.1007/s12032-014-0027-3.
[3]	吉喆, 姜玉良, 郭福新, 等. CT引导下125I粒子植入治疗放疗后复发头颈部肿瘤的临床效果. 中华放射肿瘤学杂志, 2018, 27(9): 793-797. DOI: 10.3760/cma.j.issn.1004-4221.2018.09. 001.
[4]	Qualman S. Intergroup Rhabdomyosarcoma Study: Updated for pathologist. Pediatr Dev Pathol, 1998, 1(6): 550-561. DOI: 10.1007/s100249900076.
[5]	中国抗癌协会小儿肿瘤专业委员会, 中华医学会儿科学分会血液学组, 中华医学会小儿外科学分会肿瘤组. 中国儿童及青少年横纹肌肉瘤诊疗建议(CCCG-RMS-2016). 中华儿科杂志, 2017, 55(10): 724-728. DOI: 10.3760/cma. j.issn.0578-1310.2017.10.002.
[6]	Sangkhathat S. Current management of pediatric soft tissue sarcomas. World Journal of Clinical Pediatrics, 2015, 4(4): 94- 105. DOI: 10.5409/wjcp.v4.i4.94.
[7]	刘婷, 张珂, 朱豫. 125I粒子治疗泪腺恶性和复发多形性腺瘤. 中华眼视光学与视觉科学杂志, 2018, 20(6): 335-342. DOI: 10.3760/cma.j.issn.1674-845X.2018.06.004.
[8]	Oberlin O, Rey A, Anderson J, et al. Treatment of Orbital Rhabdomyosarcoma: Survival and Late Effects of Treatment-- Results of an International Workshop. J Clin Oncol, 2001, 19(1): 197-204. DOI: 10.1016/j.jmmm.2008.10.020.
[9]	Ge X, Huang DS, Shi JT, et al. Multidisciplinary Collaborative Therapy for 30 Children with Orbital Rhabdomyosarcoma. Asian Pac J Cancer Prev, 2013, 14(8): 4641-4646. DOI: 10.7314/APJCP.2013.14.8.4641.
[10]	Rao AA, Naheedy JH, Chen JY, et al. A Clinical update and radiologic review of pediatric orbital and ocular tumors. J Oncol, 2013, 1-22. DOI: 10.1155/2013/975908.
[11]	Wolden SL, Wexler LH, Kraus DH, et al. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radia Oncol Biol Phys, 2005, 61(5): 1432-1438. DOI: 10.1016/ j.ijrobp.2004.08.005.
[12]	Curtis AE, Okcu MF, Chintagumpala M, et al. Local Control After Intensity-Modulated Radiotherapy for Head-and-Neck Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys, 2009, 73(1): 173-177. DOI: 10.1016/j.ijrobp.2008.03.029.
[13]	Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdomyosarcoma: Clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys, 2005, 63(4): 1161-1168. DOI: 10.1016/j.ijrobp.2005.03.052.
[14]	La TH, Wolden SL, Su Z, et al. Local Therapy for Rhabdomyosarcoma of the Hands and Feet: Is Amputation Necessary? A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys, 2011, 80(1): 206-212. DOI: 10.1016/ j.ijrobp.2010.01.053.
[15]	张谊, 呙芳, 张伟令, 等. 125I粒子植入术在儿童头颈部横纹肌肉瘤的临床应用. 中国当代儿科杂志, 2012, 14(6): 437-440.
[16]	Abramson DH, Fass D, Mccormick B, et al. Implant brachytherapy: a novel treatment for recurrent orbital rhabdomyosarcoma. J AAPOS, 1997, 1(3): 154-157. DOI: 10.1016/S1091-8531(97) 90058-6.
[17]	Stannard C, Maree G, Munro R, et al. Iodine-125 Orbital Brachytherapy with a Prosthetic Implant In Situ. Strahlentherapie Und Onkologie, 2011, 187(5): 322-327. DOI: 10.1007/s00066-011-2177-y.
[18]	Stannard C, Sealy R, Hering E, et al. Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy. Int J Radiat Oncol Biol Phys, 2002, 54(5): 1446-1454. DOI: 10.1016/S0360- 3016(02)03756-2.